BACKGROUND: CD40 is a receptor expressed on a wide range of cells such as leukocytes and endothelial cells (EC). As a member of the tumor necrosis factor (TNF) superfamily the activation of CD40 by CD40-ligand (CD40L) plays a crucial role for the development and progression of a variety of inflammatory processes including atherosclerosis. The aim of the present study was to investigate the effect of CD40/CD40L interaction on leukocyte adhesion to the endothelium and on endothelial cell migration. METHODS AND RESULTS: Human umbilical vein endothelial cells (HUVEC) were stimulated with either stable transfectants of mouse myeloma cells expressing the CD40L or wild type cells (4 h). Subsequently adhesion of leukocytes expressing Sialyl Lewis X, the counterpart for E-selectin (HL60 cells), was measured under shear stress (2-2.6 dyne/cm(2)) using a flow chamber adhesion assay. Stimulation of CD40 led to a significant increase of E-selectin dependent adhesion of leukocytes to the endothelium. Incubation of cells with either the CD40L blocking antibody TRAP-1 or the E-selectin blocking antibody BBA2 during CD40 stimulation completely abolished adhesion of leukocytes to HUVEC. Similar results were found in human cardiac microvasculature endothelial cells (HCMEC). In contrast stimulation of CD40 had no effect on adhesion of L-selectin expressing NALM6-L cells. Furthermore, CD40/CD40L interaction abrogated VEGF-induced migration of HUVEC compared to non-stimulated controls. In comparison experiments, stimulation of endothelial cells with VEGF led to a significant phosphorylation of ERK1/2, Akt, and eNOS. Stimulation of endothelial CD40 had no effect on VEGF-induced phosphorylation of ERK1/2. However, VEGF-induced activation of Akt and eNOS was reduced to baseline levels when endothelial CD40 was stimulated. CONCLUSION: CD40/CD40L interaction induces E-selectin dependent adhesion of leukocytes to human endothelial cells and reduces endothelial cell migration by inhibiting the Akt/eNOS signaling pathway. Copyright Â
BACKGROUND:CD40 is a receptor expressed on a wide range of cells such as leukocytes and endothelial cells (EC). As a member of the tumor necrosis factor (TNF) superfamily the activation of CD40 by CD40-ligand (CD40L) plays a crucial role for the development and progression of a variety of inflammatory processes including atherosclerosis. The aim of the present study was to investigate the effect of CD40/CD40L interaction on leukocyte adhesion to the endothelium and on endothelial cell migration. METHODS AND RESULTS:Human umbilical vein endothelial cells (HUVEC) were stimulated with either stable transfectants of mousemyeloma cells expressing the CD40L or wild type cells (4 h). Subsequently adhesion of leukocytes expressing Sialyl Lewis X, the counterpart for E-selectin (HL60 cells), was measured under shear stress (2-2.6 dyne/cm(2)) using a flow chamber adhesion assay. Stimulation of CD40 led to a significant increase of E-selectin dependent adhesion of leukocytes to the endothelium. Incubation of cells with either the CD40L blocking antibody TRAP-1 or the E-selectin blocking antibody BBA2 during CD40 stimulation completely abolished adhesion of leukocytes to HUVEC. Similar results were found in human cardiac microvasculature endothelial cells (HCMEC). In contrast stimulation of CD40 had no effect on adhesion of L-selectin expressing NALM6-L cells. Furthermore, CD40/CD40L interaction abrogated VEGF-induced migration of HUVEC compared to non-stimulated controls. In comparison experiments, stimulation of endothelial cells with VEGF led to a significant phosphorylation of ERK1/2, Akt, and eNOS. Stimulation of endothelial CD40 had no effect on VEGF-induced phosphorylation of ERK1/2. However, VEGF-induced activation of Akt and eNOS was reduced to baseline levels when endothelial CD40 was stimulated. CONCLUSION:CD40/CD40L interaction induces E-selectin dependent adhesion of leukocytes to human endothelial cells and reduces endothelial cell migration by inhibiting the Akt/eNOS signaling pathway. Copyright Â
Authors: E Terpos; M Migkou; D Christoulas; M Gavriatopoulou; E Eleutherakis-Papaiakovou; N Kanellias; M Iakovaki; I Panagiotidis; D C Ziogas; D Fotiou; E Kastritis; M A Dimopoulos Journal: Blood Cancer J Date: 2016-05-27 Impact factor: 11.037
Authors: E Eriksson; R Moreno; I Milenova; L Liljenfeldt; L C Dieterich; L Christiansson; H Karlsson; G Ullenhag; S M Mangsbo; A Dimberg; R Alemany; A Loskog Journal: Gene Ther Date: 2016-12-01 Impact factor: 5.250
Authors: A Schiza; J Wenthe; S Mangsbo; E Eriksson; Anders Nilsson; T H Tötterman; A Loskog; G Ullenhag Journal: J Transl Med Date: 2017-04-20 Impact factor: 5.531
Authors: Olha Zhenyukh; Maria González-Amor; Raul R Rodrigues-Diez; Vanesa Esteban; Marta Ruiz-Ortega; Mercedes Salaices; Sebastian Mas; Ana M Briones; Jesus Egido Journal: J Cell Mol Med Date: 2018-07-31 Impact factor: 5.310
Authors: Maria Georganaki; Mohanraj Ramachandran; Sander Tuit; Nicolás Gonzalo Núñez; Alexandros Karampatzakis; Grammatiki Fotaki; Luuk van Hooren; Hua Huang; Roberta Lugano; Thomas Ulas; Aura Kaunisto; Eric C Holland; Peter Ellmark; Sara M Mangsbo; Joachim Schultze; Magnus Essand; Sonia Tugues; Anna Dimberg Journal: Oncoimmunology Date: 2020-03-09 Impact factor: 8.110